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SELECTION OF THE MONTH 
Big Title: Algorithm for management of Abnormal LFTs 
Small titles:  
HCV reinfection and spontaneous clearance in HIV-positive MSM 
cccDNA reduction during long-term NUC treatment 
 
 
HEPATOCELLULAR CARCINOMA (HCC) 
HCC risk in chronic hepatitis B (CHB), whole genome sequencing (WGS) 
discriminates between intrahepatic and multicentric cancer, HCC as an 
exception to Model for End-Stage Liver Disease (MELD),  
It is now known that HCC can develop in patients with metabolic syndrome and without 
underlying cirrhosis. The extent to which HCC occurs in the absence of cirrhosis in 
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CHB is poorly known. Chayanupatkul et al. addressed this question in CHB patients of 
the national Veterans Administration, in the United-States of America. They show that 
less than 10% of CHB-related HCC patients did not have cirrhosis. African-American 
or Asian origin, family history of HCC, hypertension were the main risk factors for HCC 
in the absence of cirrhosis in CHB. They suggest that in the absence of cirrhosis, 
HCC surveillance should be considered for African-American and Asian 
patients, if they have a family history of HCC or are hypertensive. 
Liver cancer has a high risk of multicentric (MC) occurrence due to a strong 
carcinogenic background in the liver, in addition to a high risk of intrahepatic metastasis 
(IM). There are large differences between IM and MC with regards to their development 
and clinical outcome, but discriminating between IM and MC is usually non-trivial with 
respect to clinical or pathological aspects. Using whole-genome sequencing, Furuta et 
al. show the importance of analyzing the discrepancies between IM tumors in 
addition to IM vs. MC discrimination, before selecting a therapeutic strategy for 
multiple tumors in the liver.   
Patients listed with exception points for HCC have been more likely to be transplanted 
than those listed for chronic liver failure based on the Model for End-Stage Liver 
Disease (MELD) score. Bath et al. aimed to determine the outcomes in the 5-year 
experience of a scoring system designed to reflect the heterogeneity of tumor load of 
patients listed for HCC. They show that a novel MELD point system for HCC, taking 
into account dynamics in tumor size and number, allows for equitable liver 
allocation without compromising graft and patient survival. 
Overall survival (OS) is a composite clinical end point in HCC due to the mutual 
influence of cirrhosis and active malignancy in dictating patient's mortality. The ALBI 
grade is an index of liver dysfunction in HCC, based on albumin and bilirubin levels. 
This score lacks cross-validation, especially in intermediate-stage HCC, where OS is 
highly heterogeneous. Pinato et al. performed a retrospective analysis of the 
prognostic accuracy of the ALBI grade in estimating OS in a large, multi-center study 
including 2,426 patients (recruited in Europe, USA, and Asia), 1,461 intermediate-
stage patients treated with chemoembolization. They show that the ALBI grade is 
an accurate and reproducible prognostic marker in HCC patients, including 
those treated with chemoembolization. These findings suggest that the ALBI grade 
could serve as a stratifying biomarker of liver reserve in routine clinical practice. 
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NON-ALCOHOLIC STEATOHEPATITIS (NAFLD) 
Relationship between liver fat and cardiovascular disease risk factors 
There is mounting evidence that NAFLD conveys a higher risk of cardiovascular 
disease (CVD) events. Whether having CVD risk factors predisposes to NAFLD is not 
well known. In this issue of the Journal, Mo et al. prospectively evaluated whether liver 
fat predicted the development of CVD risk factors and whether CVD risk factors 
predicted new onset fatty liver. In a cohort of middle-aged 1,051 individuals, the 
prevalence of fatty liver was 18% at baseline. Baseline liver fat was associated with 
increased odds of incident hypertension and type 2 diabetes. In a parallel analysis, 
individuals with hypertension, hypertriglyceridemia or type 2 diabetes at 
baseline but without fatty liver had increased incident fatty liver during follow-up 
compared to individuals without those conditions. This important study clearly shows 
a bi-directional relationship between fatty liver and CVD risk factors. 
 
HEPATITIS C VIRUS (HCV) INFECTION  
Fibrosis stage-targeted treatment strategies in chronic hepatitis C - dinosaurs 
that will soon be extinct, HCV reinfection and spontaneous clearance in HIV-
positive MSM – two sides of the same coin  
The fibrosis stage-targeted treatment strategy in chronic hepatitis C aims to initiate 
treatment in patients who are most in need related to their risk of complications of liver 
disease. The strategy is based on the assumption that antiviral therapy will be offered 
to untreated patients as soon as their disease progresses. However, this strategy is 
associated with a risk of misclassifying patients because of the limits of the diagnostic 
tests of fibrosis, and does not takes into consideration the broader impact of hepatitis 
C on people's lives. The study by Deuffic-Burban et al. used a mathematical model to 
evaluate the impact of different treatment strategies in three countries, France, Italy 
and UK. Universal therapy was found to be the most effective strategy for 
reducing the 5-year incidence of cirrhosis, liver complications and liver deaths. 
This was followed by targeting individuals with ≥ F2 fibrosis scores, which still reduced 
these outcomes but not to the same extent as universal treatment. Targeting 
individuals with ≥ F3 fibrosis scores did not reduce the incidence of cirrhosis, and only 
moderately affected liver complications. Following these results – and as also outlined 
in the Editorial by Hellard et al. - guidelines that restrict access to direct acting antivirals 
are probably dinosaurs that will soon be extinct. 
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In the presence of maintained risk behaviours, HCV reinfection is of concern when 
treating patients who inject drugs or men who have sex with men (MSM) who are co-
infected with the human immunodeficiency virus (HIV). In the largest cohort studied to 
date, Ingiliz et al. quantified the rate of HCV reinfections among HIV-infected MSM 
from seven urban European areas who either cleared their initial infection 
spontaneously or were successfully treated, and investigated potential variables 
associated with repeated spontaneous viral clearance. The authors found a high 
reinfection incidence (7.3/100 person-year) estimating that almost one third of 
patients will become re-infected after 5 years. A second reinfection was observed 
in 43% among those who cleared the first reinfection, with few cases suffering also 
from a third and even fourth reinfection. The spontaneous HCV clearance rate 
increased from 15.6% after the first reinfection to 28.6% after the second one. 
Individuals who had spontaneously cleared their initial infection were more likely clear 
again spontaneously as compared to those with treatment-related clearance. The 
study confirms previous regional reports of high reinfection rates in MSM and raises 
the issue of prevention strategies in at risk populations in Europe, but also whether 
spontaneous HCV clearance may induce a partially protective immunity. 
 
HEPATITIS B VIRUS (HBV) INFECTION 
HBV surface protein amino acid substitutions underestimated, cccDNA 
reduction during long-term NUC treatment 
Quantitative hepatitis B surface antigen (HBsAg) levels are believed to be a surrogate 
marker for transcriptionally active covalently closed circular DNA (cccDNA) in 
hepatocytes and may therefore serve as an important virologic biomarker for 
evaluating disease activity as well as antiviral treatment response, especially when 
aiming for functional cure. Little, however, is known how amino acid substitutions in 
the surface protein impact its secretion and antigenicity, both of which may eventually 
influence the level of HBsAg quantification with currently available HBsAg assays. 
Hence, the aim of the study by Xiang K-H et al. was to identify novel mutations in the 
surface protein that correlated with lower HBsAg levels by using a study cohort of 230 
untreated HBeAg-positive patients. Identified were several new HBV surface 
protein substitutions outside of the ‘a’ determinant that were associated with 
lower serum HBsAg and HBV DNA levels. In vitro experiments suggested that these 
mutations may impair virion secretion, change antigenicity, or impact HBV replication 
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hereby decreasing detectable levels of HBsAg. This elegant study helps to better 
understand the mechanisms behind serum HBsAg level fluctuations, and highlights the 
caution that is needed when interpreting clinical significance of serum HBsAg levels.  
The HBV mini-chromosome, the cccDNA, which hides inside the nuclei of liver cells is 
notoriously resistant against antiviral treatment and one believes that it cannot be 
significantly reduced by oral nucleosidic polymerase inhibitors (NUCs) which inhibit 
reverse transcription only. However, cccDNA may be depleted through natural cell 
division and cell death associated with long-term NUC treatment, but this has not been 
proven yet. In the present study by Lai C-L et al. an over 99% reduction of cccDNA 
as well as total intrahepatic HBV DNA was demonstrated in liver biopsies 
obtained from patients who had been receiving continuous NUC treatment for 
up to 12 years. Whereas intrahepatic HBV pregenomic RNA was below the detection 
limit in 40% of patients, HBsAg levels were reduced by 71% only. The study suggests 
that with the currently available therapeutic agents HBsAg seroclearance may not be 
achievable in the majority of patients, but it remains to be seen whether the observed 
cccDNA reduction or depletion is sustainable and associated with better outcome. 
 
HEPATITIS DELTA VIRUS (HDV) INFECTION 
HDV-associated excess mortality in the Swiss HIV cohort 
Although it is well described that HDV accelerates the course of HBV-related liver 
disease in general, large prospective cohort studies assessing its prevalence and long-
term consequences in HIV-HBV co-infected patients under tenofovir-containing 
antiretroviral therapy are lacking. Beguelin et al. described the main epidemiological 
characteristics of HDV infection, and evaluated its impact on clinical outcomes in the 
prospective Swiss HIV Cohort Study (SHCS). Fifteen percent of HIV/HBV-infected 
patients in the SHCS were infected with HDV. These patients were twice as likely 
to die during follow-up as HDV-uninfected ones, and eight times more likely to 
die from liver disease including HCC. These results emphasize the need for 
systematic screening for HDV infection, the close monitoring of HDV-infected patients 
and underline the importance of developing and evaluating new treatments for chronic 
hepatitis D. 
 
LIVER FUNCTION TESTS 
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Performing a non-directed test battery to investigate abnormal liver function is 
cost effective 
The most common cause of a patient being referred to secondary care is for the 
investigation of an abnormal liver function test, the cause of which is unknown and not 
obvious from initial consultation. Tapper et al. report the results of an important study 
evaluating the cost-effectiveness of using two approaches by simulating data of about 
10,000 patients drawn from Britain and the US. They compared the cost-
effectiveness of a ‘non-directed’ strategy whereby a whole battery of tests was 
ordered at the outset with a ‘directed’ approach where tests were ordered in a 
step-wise manner. Their data suggests for the first time that the non-directed 
strategy is cheaper and reduces the doctor visits but generates more false 
positive results. This study may provide the basis of managing these patients better 
in the primary care. 
 
MICROBIOME AND BILIARY DISEASE 
The gut microbiota is important in modulating biliary disease 
Inflammatory biliary diseases and gut inflammation are linked leading to the suggestion 
that gut microbes in the intestine play a role in biliary inflammation. The study by 
Schrumpf et al. aimed to clarify the role of the gut microbiota in the biliary disease of 
NOD.c3c4 mice, which are known to develop biliary disease spontaneously. Their 
data show for the first time a close interaction between the microbiota and biliary 
disease as they demonstrated that germ free NOD.c3c4 mice developed a milder 
biliary disease. This study opens up a new understanding of the immunology of biliary 
inflammatory disease.  
 
PORTAL HYPERTENSION IN CHILDREN 
Children with high-risk varices should undergo primary prophylaxis 
Primary prophylaxis of variceal bleeding in cirrhotic adult patients has completely 
transformed the outlook of these patients but it is not clear whether primary prophylaxis 
is desirable in children with portal hypertension. Duche et al. describe the data obtained 
from 1,300 patients with portal hypertension both from cirrhotic and non-cirrhotic 
causes. Their data show incontrovertibly that the presence of high-risk varices 
can be defined by size and the presence of red signs and that primary 
prophylaxis is safe and associated with significantly lower risk of bleeding. This 
7 
 
paper should be the impetus to change practice and offer surveillance and primary 
prophylaxis to children at risk of variceal bleeding. 
 
LIVER TRANSPLANTATION  
Cardiac function defines posttransplant outcomes 
Assessment of cardiac function in cirrhosis and effect on posttransplant outcome is not 
clear and this may be related to the way it is measured. Ventriculo-arterial coupling 
(VAC) reflects the interaction between ventricular performance and effective arterial 
load. Shin et al. from Korea describe the data of over 900 patients in which they 
investigated alterations in VAC in cirrhotic patients and their associations with post-
liver transplant all-cause mortality over a 30-month period. Their data confirm that 
patients with cirrhosis have abnormalities in cardiac function as described 
previously and show for the first time that patients with a high VAC have a 
significantly higher mortality compared with those that have a low VAC even 
when controlling for the severity of underlying liver disease. If other investigators 
can validate these data, the methods used to assess cardiac function in cirrhotics 
undergoing transplantation will change. 
 
